NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NovoCure Ltd director Vernon W. Anthony exercised stock options to acquire 21,500 Ordinary Shares at $11.39 per share. These were option exercises rather than open-market purchases or sales. After the transactions, he directly holds 200,602 Ordinary Shares, and the exercised option grant for 21,500 shares has been fully used.
Positive
- None.
Negative
- None.
Insider Trade Summary
21,500 shares exercised/converted
Mixed
2 txns
Insider
VERNON W ANTHONY
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 21,500 | $0.00 | -- |
| Exercise | Ordinary Shares | 21,500 | $11.39 | $245K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null);
Ordinary Shares — 200,602 shares (Direct, null)
Footnotes (1)
Key Figures
Options exercised: 21,500 shares
Exercise price: $11.39 per share
Shares held after transaction: 200,602 shares
+3 more
6 metrics
Options exercised
21,500 shares
Stock Option (Right to Buy) converted into Ordinary Shares
Exercise price
$11.39 per share
Strike price for 21,500 exercised stock options
Shares held after transaction
200,602 shares
Direct Ordinary Share holdings after exercise
Exercised option grant size
21,500 shares
Underlying security shares of Stock Option (Right to Buy)
Exercise transactions
1 derivative exercise
transactionSummary exerciseCount for code M
Option expiration date
May 4, 2026
Expiration date of exercised Stock Option (Right to Buy)
Key Terms
Stock Option (Right to Buy), Ordinary Shares, derivative security, Form 4
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Form 4 regulatory
"INSIDER FILING DATA (Form 4): {"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did NovoCure (NVCR) director Vernon W. Anthony report?
Vernon W. Anthony reported exercising stock options to acquire 21,500 NovoCure Ordinary Shares. The options were exercised at $11.39 per share and converted into common equity, with no open-market buying or selling disclosed in this filing.
At what price were the NovoCure (NVCR) stock options exercised?
The stock options were exercised at $11.39 per share. This exercise price applies to 21,500 underlying Ordinary Shares, converting an existing option position into directly held NovoCure equity on the reported transaction date.
What happened to the 21,500 NovoCure (NVCR) stock options after exercise?
The 21,500 stock options were fully exercised and converted into 21,500 Ordinary Shares. Following this exercise, the Form 4 shows zero remaining shares under that specific Stock Option (Right to Buy) position for Vernon W. Anthony.
Is the NovoCure (NVCR) director transaction an open-market purchase?
The transaction is not an open-market purchase. It is classified under code “M” as an exercise or conversion of a derivative security, turning 21,500 stock options into Ordinary Shares at the fixed price of $11.39 per share.